UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~October~~ 11April 19, ~~2011~~2012

BODISEN BIOTECH, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-32616 (Commission File Number) 98-0381367 (I.R.S. Employer Identification No.)

Delaware (State or other jurisdiction of incorporation)	001-32616 (Commission File Number)	98-0381367 (I.R.S. Employer Identification No.)


Room 2001, FanMeiBuilding No. 1 NaguanZhengjie Xi’an, Shaanxi People’s Republic of China 710068 (Address of principal executive offices) (zip code)

	(86) 011-86-29-87074957
(Registrant’s telephone number, including area code)

	Not Applicable.
(Former name or former address, if changed since last report.)

~~Room~~Copies ~~2001, FanMeiBuilding~~to:

NoMarc J. 1Ross, ~~NaguanZhengjie~~Esq.

~~Xi’an,~~Sichenzia ~~Shaanxi~~Ross Friedman Ference LLP

~~People’s~~61 ~~Republic~~Broadway, of32nd ~~China 710068~~Floor,

~~(Address~~New ofYork, ~~principal~~NY ~~executive offices) (zip code)~~10006

Tel: (86212) ~~29-87074957~~930 9700

Fax: (~~Registrant’s~~212) ~~telephone~~930 ~~number, including area code)~~9725

Not Applicable.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)~~1

¨Item ~~Pre-commencement~~5.02 ~~communications~~Departure ~~pursuant~~of toDirectors ~~Rule~~or ~~14d-2(b)~~Certain ~~under~~Officers; ~~the~~Election ~~Exchange~~of ~~Act~~Directors; ~~(17~~Appointment ~~CFR~~of ~~240~~Certain Officers; Compensatory Arrangements of Certain Officers.~~14d-2(b))~~

¨On ~~Pre-commencement~~April ~~communications~~19, ~~pursuant~~2012, tothe ~~Rule~~Board ~~13e-4(c)~~of ~~under~~Directors (the ~~Exchange~~“Board”) ~~Act~~of ~~(17~~Bodisen ~~CFR~~Biotech, ~~240~~Inc.~~13e-4~~, (cthe “Company”)) elected Lin Wang as Chairman of the Board of the Company effective immediately. There is no understanding or arrangement between Lin Wang and any other person pursuant to which Lin Wang was selected as Chairman of the Board. Lin Wang is the brother of Qiong Wang, a director of the Company. Except as described above, Lin Wang does not have any family relationship with any director, executive officer or person nominated or chosen by us to become a director or executive officer. Lin Wang did not receive any compensation in connection with his appointment as Chairman of the Board.

~~Item~~Since ~~4.01~~the ~~Changes~~beginning inof ~~Registrant~~the Company’s ~~Certifying~~last ~~Accountant~~fiscal year, Mr. Wang has not been a party to any transaction, or any currently proposed transaction, in which the Company was or is to be a participant and the amount involved exceeds $120,000, or in which any related person of Mr. Wang had or will have a direct or indirect material interest.

OnMr. ~~October 11~~Wang, ~~2011~~43, has been the ~~board~~Chief Executive Officer and President of ~~directors~~the Company since April 29, 2011. He was general manager of Bodisen Biotech, Inc. ~~(the~~from ~~“Company”)~~1999 ~~ratified~~to ~~and~~2011. From ~~approved~~1997 ~~the~~to ~~Company's~~1999, ~~engagement~~Mr. ofWang ~~Clement~~worked C.at W.Yangling ~~Chan~~Kangyuan &Agricultural Chemical Co. ~~(“Clement”)~~Ltd, asa ~~independent~~fertilizer ~~auditors~~company ~~for~~where ~~the~~he ~~Company~~was ~~and~~general ~~its~~manager. Mr. ~~subsidiaries~~Wang graduated from Northwest Agriculture University in 1989. Mr. Wang Lin holds an agronomist certification.

During the years ended December 31, 2010 and 2009 and through October 11, 2011, neither the Company nor anyone on its behalf consulted Clement regarding (i) the application of accounting principles to a specific completed or contemplated transaction, (ii) the type of audit opinion that might be rendered on the Company's financial statements, or (iii) any matter that was the subject of a disagreement or event identified in response to Item ~~304(a)(1)~~8.01 ofOther ~~Regulation S-K (there being none)~~Events.

On April 19, 2012, Bo Chen stepped down as Chairman of the Board, effective immediately. Mr. Chen will remain a director of the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 13, 2011	BODISEN BIOTECH, INC.
	BODISEN BIOTECH, INC.
	By: /s/ Lin Wang
Dated: April 20, 2012	By:	/s/ Lin Wang
	~~Lin Wang~~	Lin Wang
	Chief Executive Officer
		Chairman and Chief Executive Officer

Filing Compare · BODISEN BIOTECH, INC